{"entity":{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","aka":[],"tldr":"Epidemiologist who led IBIS-I and IBIS-II, proving tamoxifen and anastrozole prevent breast cancer in high-risk women.","summary":"Jack Cuzick led the IBIS-I trial (tamoxifen) and IBIS-II (anastrozole) that established chemoprevention of breast cancer in high-risk women, and was the lead statistician of the ATAC trial that made aromatase inhibitors standard adjuvant therapy. He developed the Tyrer-Cuzick risk model and has led HPV-testing studies in cervical screening. His work continues on prevention and risk-based screening.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention"}],"tags":["prevention","epidemiology","breast"],"related":[],"cancers":["breast-hr-positive","cervical"],"sections":[],"technologies":["chemoprevention","endocrine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["ibis-i","ibis-ii"],"people":[],"bottlenecks":[],"keyPapers":["paper-ibis-i-tamoxifen-lancet-oncol-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Epidemiology, Wolfson Institute of Population Health, Queen Mary University of London","institutionId":"barts-cancer-institute","specialisms":["Breast cancer prevention","Screening epidemiology","Aromatase inhibitors","Risk prediction"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention"}],"papers":[{"title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(14)71171-4"},{"title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(19)32955-1"}]},"route":"/people/jack-cuzick/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"institution":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"}],"trial":[{"id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/"},{"id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/"}],"paper":[{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/"}]}}